Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors
ObjectiveThis study describes the characteristics, survival and prognostic factors in a cohort of patients with bone metastases (BM) from differentiated thyroid carcinoma (DTC).MethodsThis was a multicenter retrospective observational study conducted in Spain, including patients diagnosed with DTC a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1466245/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841554850509225984 |
|---|---|
| author | Suset Dueñas-Disotuar Ana Piñar-Gutiérrez Irene de Lara-Rodríguez Julia Sastre-Marcos Emma Anda-Apiñániz Amelia Oleaga-Alday JC Galofré Aida Orois Victoria Alcázar-Lázaro Laia Martínez-Guasch Cecilia Sánchez-Ragnarsson María Ángeles Gálvez-Moreno Cristina Familiar-Casado Tomás Martín-Hernández Ana R. Romero-Lluch |
| author_facet | Suset Dueñas-Disotuar Ana Piñar-Gutiérrez Irene de Lara-Rodríguez Julia Sastre-Marcos Emma Anda-Apiñániz Amelia Oleaga-Alday JC Galofré Aida Orois Victoria Alcázar-Lázaro Laia Martínez-Guasch Cecilia Sánchez-Ragnarsson María Ángeles Gálvez-Moreno Cristina Familiar-Casado Tomás Martín-Hernández Ana R. Romero-Lluch |
| author_sort | Suset Dueñas-Disotuar |
| collection | DOAJ |
| description | ObjectiveThis study describes the characteristics, survival and prognostic factors in a cohort of patients with bone metastases (BM) from differentiated thyroid carcinoma (DTC).MethodsThis was a multicenter retrospective observational study conducted in Spain, including patients diagnosed with DTC and BM between 1980 and 2022. A Cox regression analysis was performed to examine prognostic factors for survival. Kaplan-Meier and log-rank tests were performed for survival analysis and comparison between groups.ResultsA total of 133 patients were included with a median follow-up of 40 (17-70) months. Seventy patients (52.6%) had BM at the initial diagnosis. Fifty-two (39.1%) had follicular carcinoma. Sixty-six (49.6%) presented multiple BM. The most frequent location was the spine (63.2%). Other metastases were present at diagnosis in 88 (66.2%), mainly lung (60.9%). BM were treated with I131 in 91 (68.4%) patients, with BM uptake in 63 (47.4%). Fifty-six (42.1%) received treatment with multikinase inhibitors. Fifty-three (3.9%) had skeletal-related events. Seventy-two (54.1%) died. The 3-, 5- and 10-year survival was 53.5, 39.5% and 28.5%, respectively. Significant prognostic factors in the multivariate analysis were the presence of lymph node metastases (N1) HR 1.71 (95% CI 1.005-2.098; p=0.048), BM treatment with I131 HR 0.532 (95% CI 0.304-0.931; p=0.027) and age ≥67 years at BM diagnosis HR 1.991 (95% CI 1.142-3.47; p=0.015).ConclusionsSurvival of DTC patients with BM treated in a Spanish cohort was 39.5% at 5 years and 28.5% at 10 years. Patients with BM treated with I131 appear to have a better outcome in terms of mortality and the presence of lymph node involvement and age over 67 years were associated with higher mortality. |
| format | Article |
| id | doaj-art-2e647576dfab4b04b1e56969f2f80754 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-2e647576dfab4b04b1e56969f2f807542025-01-08T08:34:46ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-11-011510.3389/fendo.2024.14662451466245Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factorsSuset Dueñas-Disotuar0Ana Piñar-Gutiérrez1Irene de Lara-Rodríguez2Julia Sastre-Marcos3Emma Anda-Apiñániz4Amelia Oleaga-Alday5JC Galofré6Aida Orois7Victoria Alcázar-Lázaro8Laia Martínez-Guasch9Cecilia Sánchez-Ragnarsson10María Ángeles Gálvez-Moreno11Cristina Familiar-Casado12Tomás Martín-Hernández13Ana R. Romero-Lluch14Department of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, SpainDepartment of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, SpainDepartment of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, SpainDepartment of Endocrinology, Hospital Universitario de Toledo, Toledo, SpainDepartment of Endocrinology, Hospital Universitario de Navarra, Pamplona, SpainDepartment of Endocrinology, Hospital Universitario de Basurto, Universidad del País Vasco (UPV/EHU), Bilbao, SpainDepartment of Endocrinology, Clínica Universidad de Navarra, Pamplona, SpainDepartment of Endocrinology and Nutrition, Hospital Clínic, Barcelona, SpainDepartment of Endocrinology, Hospital Severo Ochoa, Leganés, SpainDepartment of Endocrinology, Hospital Joan XXIII, Tarragona, SpainDepartment of Endocrinology, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain0Department of Endocrinology, Hospital Universitario Reina Sofía, Córdoba, Spain1Department of Endocrinology, Hospital Clínico San Carlos, Madrid, Spain2Department of Endocrinology, Hospital Universitario Virgen Macarena, Sevilla, SpainDepartment of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, SpainObjectiveThis study describes the characteristics, survival and prognostic factors in a cohort of patients with bone metastases (BM) from differentiated thyroid carcinoma (DTC).MethodsThis was a multicenter retrospective observational study conducted in Spain, including patients diagnosed with DTC and BM between 1980 and 2022. A Cox regression analysis was performed to examine prognostic factors for survival. Kaplan-Meier and log-rank tests were performed for survival analysis and comparison between groups.ResultsA total of 133 patients were included with a median follow-up of 40 (17-70) months. Seventy patients (52.6%) had BM at the initial diagnosis. Fifty-two (39.1%) had follicular carcinoma. Sixty-six (49.6%) presented multiple BM. The most frequent location was the spine (63.2%). Other metastases were present at diagnosis in 88 (66.2%), mainly lung (60.9%). BM were treated with I131 in 91 (68.4%) patients, with BM uptake in 63 (47.4%). Fifty-six (42.1%) received treatment with multikinase inhibitors. Fifty-three (3.9%) had skeletal-related events. Seventy-two (54.1%) died. The 3-, 5- and 10-year survival was 53.5, 39.5% and 28.5%, respectively. Significant prognostic factors in the multivariate analysis were the presence of lymph node metastases (N1) HR 1.71 (95% CI 1.005-2.098; p=0.048), BM treatment with I131 HR 0.532 (95% CI 0.304-0.931; p=0.027) and age ≥67 years at BM diagnosis HR 1.991 (95% CI 1.142-3.47; p=0.015).ConclusionsSurvival of DTC patients with BM treated in a Spanish cohort was 39.5% at 5 years and 28.5% at 10 years. Patients with BM treated with I131 appear to have a better outcome in terms of mortality and the presence of lymph node involvement and age over 67 years were associated with higher mortality.https://www.frontiersin.org/articles/10.3389/fendo.2024.1466245/fullthyroid cancerbone metastasessurvivalskeletal-related eventsradioiodinemultikinase inhibitors; antiresorptive agents |
| spellingShingle | Suset Dueñas-Disotuar Ana Piñar-Gutiérrez Irene de Lara-Rodríguez Julia Sastre-Marcos Emma Anda-Apiñániz Amelia Oleaga-Alday JC Galofré Aida Orois Victoria Alcázar-Lázaro Laia Martínez-Guasch Cecilia Sánchez-Ragnarsson María Ángeles Gálvez-Moreno Cristina Familiar-Casado Tomás Martín-Hernández Ana R. Romero-Lluch Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors Frontiers in Endocrinology thyroid cancer bone metastases survival skeletal-related events radioiodine multikinase inhibitors; antiresorptive agents |
| title | Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors |
| title_full | Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors |
| title_fullStr | Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors |
| title_full_unstemmed | Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors |
| title_short | Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors |
| title_sort | bone metastasis in differentiated thyroid cancer spanish multicenter study of clinical characteristics survival and prognostic factors |
| topic | thyroid cancer bone metastases survival skeletal-related events radioiodine multikinase inhibitors; antiresorptive agents |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1466245/full |
| work_keys_str_mv | AT susetduenasdisotuar bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT anapinargutierrez bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT irenedelararodriguez bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT juliasastremarcos bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT emmaandaapinaniz bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT ameliaoleagaalday bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT jcgalofre bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT aidaorois bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT victoriaalcazarlazaro bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT laiamartinezguasch bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT ceciliasanchezragnarsson bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT mariaangelesgalvezmoreno bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT cristinafamiliarcasado bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT tomasmartinhernandez bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors AT anarromerolluch bonemetastasisindifferentiatedthyroidcancerspanishmulticenterstudyofclinicalcharacteristicssurvivalandprognosticfactors |